Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The PRIMA subretinal implant is generating buzz in retinal care, with 36-month data showing durable vision gains in patients with advanced geographic atrophy (GA). A panel of retina specialists also discussed photobiomodulation, Encelto for macular telangiectasia, and the anticipated oral agent tinlarebant for Stargardt disease — painting a picture of a rapidly evolving treatment landscape.
The retina field is seeing a wave of new and emerging therapies. At a Healio | OSN Retina Roundtable, leading specialists discussed the PRIMA photovoltaic subretinal implant (Science Corporation) for atrophic age-related macular degeneration (AMD). Already CE mark–approved in the EU, 36-month data showed durable vision gains — including the ability for some patients to read — with more than 80% of adverse events occurring in the first 6 months. Experts noted a ~15% serious adverse event rate (including retinal detachment and macular hole), but highlighted the implant's potential regulatory advantage over cell therapy, given its faster device-based approval pathway.
The panel also weighed in on photobiomodulation (PBM), with some practices already offering it. While the registration study had a solid design, experts called for larger prospective trials to confirm efficacy. On the inherited retinal disease front, Encelto (revakinagene taroretcel-lwey) for macular telangiectasia continues to face real-world access and formulary challenges, while oral tinlarebant for Stargardt disease type 1 is anticipated for potential FDA approval in February 2027.
Key Takeaways:
Why it matters: For the first time, patients with advanced GA may have a realistic path to functional reading vision. Combined with disease-modifying agents and emerging oral therapies for inherited retinal diseases, the field is entering a new era of complementary, multi-pronged treatment strategies.